Within Host Dynamics of SARS-CoV-2 in Humans: Modeling Immune Responses and Antiviral Treatments

被引：44
作者：
Ghosh I. [1 ]
机构：
[1] Department of Computational and Data Sciences, Indian Institute of Science, Karnataka, Bengaluru
来源：
SN Computer Science | 2021年 / 2卷 / 6期
基金：
英国科研创新办公室;
关键词：
Immune response; Model calibration; Numerical simulation; Sars-CoV-2; Treatments;
D O I：
10.1007/s42979-021-00919-8
中图分类号：
学科分类号：
摘要：
In December 2019, a newly discovered SARS-CoV-2 virus was emerged from China and propagated worldwide as a pandemic, resulting in about 3–5% mortality. Mathematical models can provide useful scientific insights about transmission patterns and targets for drug development. In this study, we propose a within-host mathematical model of SARS-CoV-2 infection considering innate and adaptive immune responses. We analyze the equilibrium points of the proposed model and obtain an expression of the basic reproduction number. We then numerically show the existence of a transcritical bifurcation. The proposed model is calibrated to real viral load data of two COVID-19 patients. Using the estimated parameters, we perform global sensitivity analysis with respect to the peak of viral load. Finally, we study the efficacy of antiviral drugs and vaccination on the dynamics of SARS-CoV-2 infection. Results suggest that blocking the virus production from infected cells can be an effective target for antiviral drug development. Finally, it is found that vaccination is more effective intervention as compared to the antiviral treatments. © The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd 2021.
引用
收藏
相关论文
共 47 条
[1]  
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Et al., Clinical features of patients infected with 2019 novel coronavirus in wuhan, china, Lancet, 395, 10223, pp. 497-506, (2020)
[2]  
Gumel A.B., Ruan S., Day T., Watmough J., Brauer F., van den Driessche P., Gabrielson D., Bowman C., Alexander M.E., Ardal S., Et al., Modelling strategies for controlling Sars outbreaks, Proc Royal Soc Lond Ser B Biol Sci, 271, 1554, pp. 2223-2232, (2004)
[3]  
Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Et al., Angiotensin-converting enzyme 2 is a functional receptor for the sars coronavirus, Nature, 426, 6965, pp. 450-454, (2003)
[4]  
de Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., Fouchier R.A.M., Galiano M., Gorbalenya A.E., Memish Z.A., Et al., Commentary: Middle east respiratory syndrome coronavirus (mers-cov): Announcement of the coronavirus study group, J Virol, 87, 14, pp. 7790-7792, (2013)
[5]  
de Wit E., van Doremalen N., Falzarano D., Munster V.J., Sars and mers: Recent insights into emerging coronaviruses, Nat Rev Microbiol, 14, 8, (2016)
[6]  
Cowling Benjamin J., Minah Park, Fang Vicky J, Peng Wu, Leung Gabriel M, Wu Joseph T. Preliminary epidemiologic assessment of mers-cov outbreak in south korea, may-june 2015, Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles= European Communicable Disease Bulletin, 20, 25, (2015)
[7]  
Kim K.H., Tandi T.E., Choi J.W., Moon J.M., Kim M.S., Middle east respiratory syndrome coronavirus (mers-cov) outbreak in south korea, 2015: Epidemiology, characteristics and public health implications, J Hosp Infect, 95, 2, pp. 207-213, (2017)
[8]  
Sardar T., Ghosh I., Rodo X., Chattopadhyay J., A realistic two-strain model for mers-cov infection uncovers the high risk for epidemic propagation, Plos Neglect Trop Dis, 14, 2, (2020)
[9]  
On K.K., Tang A., Wei Vivian W.I., Woo H.P., Eng K.Y., Riley S., Epidemic models of contact tracing: Systematic review of transmission studies of severe acute respiratory syndrome and middle east respiratory syndrome, Comput Struct Biotechnol J, 17, (2019)
[10]  
Soin A.S., Kumar K., Choudhary N.S., Sharma P., Mehta Y., Kataria S., Govil D., Deswal V., Chaudhry D., Singh P.K., Et al., Tocilizumab plus standard care versus standard care in patients in india with moderate to severe covid-19-associated cytokine release syndrome (covintoc): An open-label, multicentre, randomised, controlled, phase 3 trial, Lancet Respir Med, 9, 5, pp. 511-521, (2021)
12345